July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
The effects of rebamipide-based gene-expression analysis in human conjunctival epithelial cells
Author Affiliations & Notes
  • Keiko Yamada
    Ophthalmology, North Medical Center of Kyoto Prefectural University of Med, Kyoto, Japan
  • Mayumi Ueta
    Frontier Medical Science and Technology for Ophthalmology, Kyoto Prefectural University of Med, Kyoto, Japan
  • Hiromi Nishigaki
    Frontier Medical Science and Technology for Ophthalmology, Kyoto Prefectural University of Med, Kyoto, Japan
  • Norihiko Yokoi
    Ophthalmology, Kyoto Prefectural University of Med, Kyoto, Japan
  • Chie Sotozono
    Ophthalmology, Kyoto Prefectural University of Med, Kyoto, Japan
  • Shigeru Kinoshita
    Frontier Medical Science and Technology for Ophthalmology, Kyoto Prefectural University of Med, Kyoto, Japan
  • Footnotes
    Commercial Relationships   Keiko Yamada, None; Mayumi Ueta, None; Hiromi Nishigaki, None; Norihiko Yokoi, None; Chie Sotozono, None; Shigeru Kinoshita, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 116. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Keiko Yamada, Mayumi Ueta, Hiromi Nishigaki, Norihiko Yokoi, Chie Sotozono, Shigeru Kinoshita; The effects of rebamipide-based gene-expression analysis in human conjunctival epithelial cells. Invest. Ophthalmol. Vis. Sci. 2018;59(9):116.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : It is reported that rebamipide (RBM), an eye-drop medicine used to treat dry eye in Japan, suppresses ocular-surface inflammation. The purpose of this present study was to determine the effects of RBM-based gene-expression analysis in primary human conjunctival epithelial cells (PHCjECs).

Methods : This study involved 3 female conjunctivochalasis (CCh) patients (mean age: 69±15 years) in whom informed consent was obtained after receiving a detailed explanation of the study protocols. PHCjECs were harvested from conjunctival tissues obtained and discarded at the time of CCh surgery. The harvested PHCjECs were cultured using purified dispase, were divided into two groups [i.e., polyI:C(10µg/ml) added group and polyI:C(10µg/ml)+RBM(2mM) added group], and were stimulated for 3 hours. An exhaustive gene-expression analysis was then performed to compare gene-expressions in both groups using the GeneChip Microarray System (Thermo Fisher Scientific, Waltham, MA).

Results : GeneChip Microarray analysis showed that in the PHCjECs, eighteen transcripts [e.g., NmrA-like family domain containing 1 pseudogene (LOC344887), PR domain containing 1 with ZNF domain (PRDM1), and growth differentiation factor 15 (GDF 15)] were upregulated 1.5-fold more upon polyI:C stimulation with RBM than upon polyI:C stimulation without RBM in all 3 cases. In addition, six transcripts [e.g., myxovirus resistance 2 (MX2), RGM domain family-member B (RGMB), and v-myc myelocytomatosis viral oncogene homolog (nMyc)] were downregulated 0.6-fold less upon polyI:C stimulation with RBM than upon polyI:C stimulation without RBM in all 3 cases.

Conclusions : The findings of this study show that RBM was effective in both upregulating and suppressing various kinds of gene expressions in PHCjECs stimulated with polyI:C. Further study using quantitative real-time polymerase chain reaction is needed to confirm these upregulated or downregulated transcripts of their gene-expressions, and it is essential to elucidate the method by which each gene acts in the action mechanism of RBM on the ocular surface.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×